Johnson & Johnson

JNJ · NYSE

Johnson & Johnson reported FY2025 revenue of $94.2 billion, FY2025 net income of $26.8 billion and 2026 Q1 revenue of $24.1 billion. The thesis depends on pharma growth, medtech execution, litigation outcomes and cash conversion.

Follow Add to Watchlist Ask Question

NYSE JNJ Coverage Bootstrap Johnson & Johnson

Latest ReportMay 19, 2026Johnson & Johnson: the healthcare compounder has to keep litigation from swallowing the pipelineView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

NYSE

Clear tags

Latest Thesis

Johnson & Johnson: the healthcare compounder has to keep litigation from swallowing the pipeline

May 19, 2026Research reportSlides available

Read report Open slides Discussion (0)

Johnson & Johnson& Johnson: the healthcare compounder has to keep litigation fromMay 19, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Johnson & Johnson: the healthcare compounder has to keep litigation from swallowing the pipelineJohnson & Johnson reported FY2025 revenue of $94.2 billion, FY2025 net income of $26.8 billion and 2026 Q1 revenue of $24.1 billion. The thesis depends on pharma growth, medtech execution, litigation outcomes and cash conversion.NYSEMay 19, 2026Research reportRead Slides